The HAM Infliximab Study

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
HTLV-I-associated Myelopathy
Interventions
DRUG

Infliximab

Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study

Trial Locations (1)

W2 1PG

Imperial College Healthcare NHS Trust, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medical Research Council

OTHER_GOV

lead

Imperial College London

OTHER